Remember meForgot password?
    Log in with Twitter

article imageDisruptions in store for pharmaceuticals in 2018

By Tim Sandle     Dec 20, 2017 in Business
New technologies, cloud computing, and wider use of risk assessment are among the continuing changes that are disrupting the pharmaceutical sector. Expect 2018 to see the pace of change to accelerate.
According to analysts at Veeva System in conversation with Outsoruced Pharma, 2018 will see further shake up of the drug development market. These changes fall into four broad themes.
Integration of department functions
Like any major corporation, a typical pharmaceutical organization is bureaucratic and segmented into different departments. To enable drug innovation to progress smoothly the so-called ‘silo mentality’ needs to be overcome and new ways found for departments like manufacturing, quality and regulatory to work together. Key to this is ensuring that quality and compliance become the responsibility of all in the organization.
Automation of the regulatory process
The regulatory process is key to getting different drugs licensed in different territories. This process is reliant upon information provided by the quality debarment. The process is often lengthy; as a result many regulatory functions are seeking different ways to automate the process. This includes the electronic exchange of information so that product dossiers can be easily updated across a number of platforms.
An example of such a service is IQVIA, which provides software to help manage the drug application process.
Many pharmaceutical companies are electing to outsource much of the clinical trials program to Contract Research Organizations. Due to the competitive landscape, many of these organizations are developing new business models, shifting for being simple service providers and instead seeking greater collaboration with pharmaceutical companies. For this to happen the technical and data environments, within these organizations, require modernization.
With this technical consultants Diaspark have been helping Contract Research Organizations to accelerate the drug development process across web, mobile and cloud services.
Cloud first strategy
Many pharmaceutical organizations are adopting a ‘cloud first’ strategy. This enables companies to streamline services across multiple sites and to facilitate greater collaborative working across business units. This enables suppliers and contractors to also work with the core company.
Drivers for cloud services include an increasing need to develop personalized medicines; the development, through mergers and acquisitions, of many pharmaceutical organizations to become huge, competing conglomerates; and the desire for greater cost-saving measures.
More about Pharmaceuticals, Pharmacy, Medicines, Drugs
Latest News
Top News